2020
DOI: 10.1007/s12325-020-01466-z
|View full text |Cite
|
Sign up to set email alerts
|

Terlipressin May Decrease In-Hospital Mortality of Cirrhotic Patients with Acute Gastrointestinal Bleeding and Renal Dysfunction: A Retrospective Multicenter Observational Study

Abstract: Background: Acute gastrointestinal bleeding (GIB) rapidly reduces effective blood volume, thereby precipitating acute kidney injury (AKI). Terlipressin, which can induce splanchnic vasoconstriction and increase renal perfusion, has been recommended for acute GIB and hepatorenal syndrome in liver cirrhosis. Thus, we hypothesized that terlipressin might be beneficial for cirrhotic patients with acute GIB and renal impairment. Methods: In this Chinese multi-center study, 1644 cirrhotic patients with acute GIB wer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
9
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 40 publications
1
9
0
Order By: Relevance
“…Patients with more severe stages of AKI, i.e., stages 2 and 3, had the higher odds of mortality compared to those with stages 1A. This is similar to a study conducted by Xu et al [21]. The variations among mortality rates maybe as a result of differences in the study populations, the underlying precipitating factors of AKI, etiology and severity of liver disease, stage of AKI, and resources available for managing the patients.…”
Section: Discussionsupporting
confidence: 85%
See 2 more Smart Citations
“…Patients with more severe stages of AKI, i.e., stages 2 and 3, had the higher odds of mortality compared to those with stages 1A. This is similar to a study conducted by Xu et al [21]. The variations among mortality rates maybe as a result of differences in the study populations, the underlying precipitating factors of AKI, etiology and severity of liver disease, stage of AKI, and resources available for managing the patients.…”
Section: Discussionsupporting
confidence: 85%
“…The variations among mortality rates maybe as a result of differences in the study populations, the underlying precipitating factors of AKI, etiology and severity of liver disease, stage of AKI, and resources available for managing the patients. Vasoactive drugs such as terlipressin have been found to improve the outcome of patients with liver cirrhosis and AKI, especially those precipitated by gastrointestinal bleeding [21]. None of the patients in this study was administered with terlipressin or any other vasoactive drugs because of nonavailability at the study site.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In the second part, we retrospectively selected patients with cirrhosis and with acute gastrointestinal bleeding (AGIB) who received terlipressin and/or somatostatin/octreotide from our multicenter study (registration number: NCT03846180), which has been further updated after some publications (11)(12)(13)(14). Notably, in this part, the eligible patients were consecutively admitted to 13 centers from 8 provinces or municipalities in China between January 2010 and December 2018, and patients who underwent transjugular intrahepatic portosystemic shunt, splenectomy, surgical shunt, or liver transplantation were excluded from the study.…”
Section: Methodsmentioning
confidence: 99%
“…Of these studies, only two small-scale have studies used the new AKI diagnostic criteria [ 14 , 20 ]. In the most recent study in China, large-scale retrospective results using ICA criteria were published [ 21 ]. However, the incidence rates of ICA-AKI and conventional AKI in cirrhotic patients with acute gastrointestinal bleeding were 7.1% and 5.0%, respectively, which are very low compared with those in previous studies.…”
Section: Discussionmentioning
confidence: 99%